Covid-19: Director General of Pasteur Institute answers questions related to PCR, vaccine, Pfizer, virus rebound, recrudescence

The Director General of the Pasteur Institute in Algeria, Doctor Fawzi Derrar, tackled the issue of the acquisition of the vaccine against the coronavirus (covid-19).

0
79
Pfizer Algeria Coronavirus Covid-19 vaccine Pasteur Institute

The Director General of the Pasteur Institute in Algeria, Doctor Fawzi Derrar, tackled the issue of the acquisition of the vaccine against the coronavirus (covid-19).

In an interview granted to liberty newspaper, the Director General of the Pasteur Institute of Algeria, Doctor Fawzi Derrar, emphasized that “members of the scientific committee in charge of the monitoring of the development of the Coronavirus pandemic in Algeria, held a technical meeting with the vaccine producers and the representatives of Pfizer
to “ address all the aspects inherent to this new vaccine, in particular this new immunization product’s technical and logistical ones ”.

“We will have to negotiate the logistical aspect which is very important and may even have an impact on the vaccination campaign. consequently, it will be necessary to find and acquire the solutions in relation to our already existing vaccination system ”, explained doctor derrar.

Commenting on this meeting, the Director General of the Pasteur Institute of Algeria indicated that “in addition to the two aforementioned vaccines, there are others which will still be released. “.

“There is also the possibility of going through the United Nations Covax system, which guarantees access to the vaccine. The Covax system will make it possible to acquire the vaccine two to three times cheaper than buying it directly from a manufacturer, ”he said.

“We have also received other suppliers before the pfizer group. we had the opportunity to negotiate with other American, European, Chinese and even Russian leboratories. we are studying all the parameters, as well as the advantages offered by each of them”, he added in the same vein.

In addition, Doctor Derrar indicated that, during the meeting with the representatives of Pfizer, the debates focused on “all the aspects and advantages linked to their vaccine, which could be among the first available on the market “.

According to the same official, the question related to the impact of vaccine on our health system was also addressed, because “it will be necessary to take into account certain logistical aspects, since it is a vaccine of a new generation “.

“We must implement the appropriate means of transport and logistics to acquire such an immunization product which is very fragile, ”he explained.

“The most important thing is to plan to start a vaccination campaign immediately after the authorizations for use have been issued. it will therefore already be necessary to put in place a whole plenning of doses and the categories to be vaccinated initially, such as healthcare workers and people at risk, ”he explained.

in the same context, the Director said that the pharmaceutical producer groups “offer vaccines in the form of sale, supply and installation”, adding that “our vaccination system must be able to adapt to the conditions of these so-called new generation vaccines ”.

Moreover, and questioned on the management of the second wave of coronavirus by the virologists of the Institut Pasteur, Doctor derrar highlighted that “this recrudescence and the virus rebound were expected”, and that “the Pasteur Institute of Algeria was well prepared to face this epidemic rise ”.

“It should be noted, in this regard, that the the Institute covers a rate that oscillates between 60 and 65% of diagnostic pcr test samples performed nationally. in other words, we provide diagnosis for the majority of the tests carried out in the country, “said the director of the IPA.

for Dr derrar, “the institute was able to benefit from the experience of the first wave, when there was such a terrible pressure on screening tests.” to this end, he explained that “this pressure was explained by the fact that there was not a network of leboratories specialized in the treatment of pcr”, however, “today, things are clearly improved, in particular with the contribution of a number of public and private laboratories, even if some have suffered stoppages due to lack of reagents ”.

“Despite the increase in the number of cases of covid infection recorded daily, the situation is not as tense at the ipa level. we implemented a small reorganization within the establishment, which made it possible and easier for several laboratories to get started in the diagnosis of covid. There is also another positive element which is not the least, it is the acquisition of certain automatons “, he further detailed.

In this vein, he also pointed out that “until last week, 45 public leboratories and about twenty others under private law were validated and approved by the ipa”.

“We are running around 2,500 samples per day, obviously adding those covered by all the ipa annexes in constantine and oran. for the private sector, I do not yet have a precise, said Dr Derrar, number of samples processed per day.

Algerie 360

LEAVE A REPLY

Please enter your comment!
Please enter your name here